Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).
Ombitasvir/Paritaprevir/Ritonavir and dasabuvir combination treatment in patients with HIV/HCV co-infection: results of an italian compassionate use program / Massimo, A., Teti, E., Antinori, A., Milazzoi, L., Sollima, S., Rizzardini, G., Di Biagio, A., Saracino, A., Bruno, R., Borghi, V., De Luca, A., Cattelan, A., Hasson, H., Taliani, G., Monforte, A.D., Mastroianni, C.M., Di Perri, G., Bigoni, S., Puoti, M., Spinetti, A., et al.. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 64:5(2017), pp. 680-683. [10.1093/cid/ciw846]
Ombitasvir/Paritaprevir/Ritonavir and dasabuvir combination treatment in patients with HIV/HCV co-infection: results of an italian compassionate use program
TALIANI, Gloria;MASTROIANNI, Claudio Maria;VULLO, Vincenzo;PENNICA, Alfredo;PASQUAZZI, Caterina;
2017
Abstract
Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).| File | Dimensione | Formato | |
|---|---|---|---|
|
Andreoni_Ombitasvir_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
864.72 kB
Formato
Adobe PDF
|
864.72 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
